Back to Search
Start Over
Recent advances and new strategies on leishmaniasis treatment
- Source :
- Applied Microbiology and Biotechnology. 104:8965-8977
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- Leishmaniasis is one of the most important tropical neglected diseases according to the World Health Organization. Even after more than a century, we still have few drugs for the disease therapy and their great toxicity and side effects put in check the treatment control program around the world. Moreover, the emergence of strains resistant to conventional drugs, co-infections such as HIV/Leishmania spp., the small therapeutic arsenal (pentavalent antimonials, amphotericin B and formulations, and miltefosine), and the low investment for the discovery/development of new drugs force researchers and world health agencies to seek new strategies to combat and control this important neglected disease. In this context, the aim of this review is to summarize new advances and new strategies used on leishmaniasis therapy addressing alternative and innovative treatment paths such as physical and local/topical therapies, combination or multi-drug uses, immunomodulation, drug repurposing, and the nanotechnology-based drug delivery systems.Key points• The treatment of leishmaniasis is a challenge for global health agencies.• Toxicity, side effects, reduced therapeutic arsenal, and drug resistance are the main problems.• New strategies and recent advances on leishmaniasis treatment are urgent.• Immunomodulators, nanotechnology, and drug repurposing are the future of leishmaniasis treatment.
- Subjects :
- medicine.medical_specialty
Antiprotozoal Agents
Context (language use)
Drug resistance
Applied Microbiology and Biotechnology
World health
03 medical and health sciences
Drug Delivery Systems
Amphotericin B
medicine
Global health
Humans
Intensive care medicine
Leishmaniasis
030304 developmental biology
Leishmania
0303 health sciences
Miltefosine
030306 microbiology
business.industry
Neglected Disease
General Medicine
medicine.disease
Drug repositioning
business
Biotechnology
medicine.drug
Subjects
Details
- ISSN :
- 14320614 and 01757598
- Volume :
- 104
- Database :
- OpenAIRE
- Journal :
- Applied Microbiology and Biotechnology
- Accession number :
- edsair.doi.dedup.....f933e143955857c6de6d86ab4b0c52b4
- Full Text :
- https://doi.org/10.1007/s00253-020-10856-w